Utilization of Risankizumab and Comparator Products: A Descriptive Analysis

In this report, we assessed utilization patterns of risankizumab, guselkumab, tildrakizumab, ustekinumab, secukinumab, ixekizumab, and brodalumab in the Merative™ Marketscan® Research Databases.

The study period includes data from April 23, 2019 to December 31, 2022. We ran this request on the Merative™ Marketscan® Research Databases on December 11, 2023.